Unfavorably altered fibrin clot properties are associated with recurrent venous thromboembolism in patients following post‑discharge events [0.03%]
出院后事件患者的复发性静脉血栓栓塞与不利改变的纤维蛋白凝块特性有关
Kamila W Undas,Jakub Siudut,Michał Ząbczyk
Kamila W Undas
A nomogram to predict in‑hospital mortality in post-cardiac arrest patients: a retrospective cohort study [0.03%]
一项预测心脏骤停后患者院内死亡率的列线图：回顾性队列研究
Jun Chen,Ziwei Mei,Yimin Wang et al.
Jun Chen et al.
Introduction: Nomograms of prognosis in patients with a history of cardiac arrest (CA) have been established. However, there are some shortcomings and interferences in their clinical application. ...
Michał Aporowicz,Hubert Szyller,Marcin Ziętek et al.
Michał Aporowicz et al.
Irritable bowel syndrome following COVID-19: an underestimated consequence of SARS-CoV-2 infection [0.03%]
COVID-19后的肠易激综合征：SARS-CoV-2感染的被低估的后果
Anna Nazarewska,Konrad Lewandowski,Magdalena Kaniewska et al.
Anna Nazarewska et al.
Introduction: Gastrointestinal (GI) symptoms are a common manifestation of COVID‑19. Objectives: We aimed to investigate whether GI sy...
Jarosław Dulski,Rana H Al-Shaikh,Anna Sulek et al.
Jarosław Dulski et al.
Przemysław Sikora,Ryszard Grenda,Małgorzata Kowalczyk et al.
Przemysław Sikora et al.
Introduction: Nephropathic cystinosis (NC) is a rare, autosomal recessive disorder leading to lysosomal accumulation of cystine. It is caused by mutations in the CTNS gene encoding a cystine cotransporter cystinosin. The ...
Relative superiority of the revised Lund-Malmö equation over 22 other equations used for glomerular filtration rate estimation in undialyzed patients with end-stage renal disease [0.03%]
未透析终末期肾病患者估算肾小球滤过率的Lund-Malmö修订方程较其他22种方法更为优越
Danyang Zhang,Liping Fu,Shimin Jiang et al.
Danyang Zhang et al.
Introduction: The glomerular filtration rate (GFR) is an important indicator of renal function, and its precise measurement is essential for guiding clinical management. However, studies evaluating the performance of GFRe...
Juan R Rey,Juan Caro-Codón
Juan R Rey
Anetta Undas
Anetta Undas
Will sustained biological therapy improve long‑term outcome in inflammatory bowel disease? [0.03%]
维持生物制剂治疗能改善炎症性肠病的长期预后吗？
Pär Myrelid,Michael Eberhardson
Pär Myrelid